Sign up to watch this video
Free access to all Sound Bites content
Dr. Joshua Reuss reviews additional efficacy endpoints in treatment naïve population from the BEAMION trial of zongertinib in HER2m NSCLC (Video 2/3)
Published 1 week
Medical Professional
BEAMION secondary efficacy
Related Videos
Dr. Martin Dietrich reviews the evidence trastuzumab deruxtecan (T-Dxd) in gastric cancer (Video 2/3)
Martin Dietrich
Dr. Edgardo Santos discusses the emergence of SQ amivantamab+lazertinib in 1L EGFRm mNSCLC (Video 1/3)
Edgardo Santos, MD
Dr. Manali Kamdar discusses the curative potential of 2L CAR-T with liso-cel in R/R LBCL (Video 1/3)
Manali Kamdar, MD
Dr. Joshua Reuss reviews additional efficacy endpoints in treatment naïve population from the BEAMION trial of zongertinib in HER2m NSCLC (Video 2/3)
Joshua Reuss, MD
Dr. Himisha Beltran discusses a paradigm shift for BRCA2 mutations in prostate cancer (Video 1/3)
Himisha Beltran, MD
Dr. Amer Zeidan discusses insights on anemia in lower-risk MDS and the use of luspatercept (Video 1/3)
Amer Zeidan, MD
IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America
© 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.